Nagi El Saghir
American University of Beirut
H-index: 44
Asia-Lebanon
Top articles of Nagi El Saghir
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline
JCO global oncology
2024/1
57MO First-line (1L) ribociclib (RIB)+ endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and …
Annals of Oncology
2023/11/1
PO119 SURVIVAL OF YOUNG PATIENTS WITH ADVANCED BREAST CANCER STAGES III AND IV
The Breast
2023/10/1
456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB)+ endocrine therapy (ET) vs combination chemotherapy (combo CT) in …
Annals of Oncology
2023/10/1
402P First-line ribociclib (RIB)+ endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of …
Annals of Oncology
2023/10/1
Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon
Gene
2023/6/30
Hazem Assi
H-Index: 12
Georges Chahine
H-Index: 2
Nagi El Saghir
H-Index: 26
Mohammad Haidar
H-Index: 10
Rami Mahfouz
H-Index: 21
Outcomes with first-line (1L) ribociclib (RIB)+ endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts …
2023/6/1
Improved survival of young patients with breast cancer 40 years and younger at diagnosis
JCO Global Oncology
2023/5
Sarcoidosis mimicking a malignant metastatic disease
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
2023/1
The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study
BMC cancer
2022/12
Maya Charafeddine
H-Index: 13
Deborah Mukherji
H-Index: 21
Nagi El Saghir
H-Index: 26
Ali Shamseddine
H-Index: 26
Pathogenic mutations in ethnic Lebanese Arab patients with high risk for hereditary breast cancer
European Journal of Cancer
2022/11/1
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced …
Clinical Cancer Research
2022/3/1
Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3 …
Cancer Research
2022/2/15
Access to cancer treatment and diagnosis in the Eastern Mediterranean Region
EASTERN MEDITERRANEAN REGION SPECIAL REPORT
2022
Genetic counseling, screening and risk-reducing surgery in patients with primary breast cancer and germline BRCA mutations: Unmet needs in low-and middle-income countries
European Journal of Breast Health
2022/1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a …
Annals of Oncology
2021/10/1
BReast CAncer gene (BRCA): snapshot of the Middle East
Chinese Clinical Oncology
2021/10
Implemented Interventions at the Naef K. Basile Cancer Institute to protect patients and medical personnel From COVID infections: effectiveness and patient satisfaction
Frontiers in Oncology
2021/6/10
Breast-gynaecological & immuno-oncology international cancer conference (BGICC) consensus and recommendations for the management of triple-negative breast cancer
Cancers
2021/5/8
93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC …
Annals of Oncology
2021/5/1
Co-Authors
